



10/517707

Rec'd PCT/PTO 10 DEC 2004

Bescheinigung      Certificate

Attestation

REC'D	01 SEP 2003
WIPO	PCT

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02012911.0

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk



PCT/EP03/06055

Anmeldung Nr:  
Application no.: 02012911.0  
Demande no:

Anmelddatag:  
Date of filing: 11.06.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

MERCK PATENT GmbH  
Frankfurter Strasse 250  
64293 Darmstadt  
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

Modified bryodin 1

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

C07K14/00

Am Anmelddatag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignés lors du dépôt:

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

## MODIFIED BRYODIN 1

### FIELD OF THE INVENTION

The present invention relates to polypeptides to be administered especially to humans and in particular for therapeutic use. The polypeptides are modified polypeptides whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention in particular relates to the modification of bryodin 1 to result in bryodin 1 proteins that are substantially non-immunogenic or less immunogenic than any non-modified counterpart when used *in vivo*.

10 The invention relates furthermore to T-cell epitope peptides derived from said non-modified protein by means of which it is possible to create modified bryodin 1 variants with reduced immunogenicity.

### BACKGROUND OF THE INVENTION

15 There are many instances whereby the efficacy of a therapeutic protein is limited by an unwanted immune reaction to the therapeutic protein. Several mouse monoclonal antibodies have shown promise as therapies in a number of human disease settings but in certain cases have failed due to the induction of significant degrees of a human anti-murine antibody (HAMA) response [Schroff, R. W. et al (1985) *Cancer Res.* 45: 879-885; Shawler, D.L. et al (1985) *J. Immunol.* 135: 1530-1535]. For monoclonal antibodies, a number of techniques have been developed in attempt to reduce the HAMA response [WO 89/09622; EP 0239400; EP 0438310; WO 91/06667]. These recombinant DNA approaches have generally reduced the mouse genetic information in the final antibody construct whilst increasing the human genetic information in the final construct.

20 Notwithstanding, the resultant "humanized" antibodies have, in several cases, still elicited an immune response in patients [Issacs J.D. (1990) *Sem. Immunol.* 2: 449, 456; Rebello, P.R. et al (1999) *Transplantation* 68: 1417-1420].

25 Antibodies are not the only class of polypeptide molecule administered as a therapeutic agent against which an immune response may be mounted. Even proteins of human origin and with the same amino acid sequences as occur within humans can still induce an immune response in humans. Notable examples include the therapeutic use of granulocyte-macrophage colony stimulating factor [Wadhwa, M. et al (1999) *Clin.*

*Cancer Res.* 5: 1353-1361] and interferon alpha 2 [Russo, D. et al (1996) *Bri. J. Haem.* 94: 300-305; Stein, R. et al (1988) *New Engl. J. Med.* 318: 1409-1413] amongst others.

A principal factor in the induction of an immune response is the presence within the  
5 protein of peptides that can stimulate the activity of T-cells via presentation on MHC  
class II molecules, so-called "T-cell epitopes". Such potential T-cell epitopes are  
commonly defined as any amino acid residue sequence with the ability to bind to MHC  
Class II molecules. Such T-cell epitopes can be measured to establish MHC binding.  
Implicitly, a "T-cell epitope" means an epitope which when bound to MHC molecules can  
10 be recognized by a T-cell receptor (TCR), and which can, at least in principle, cause the  
activation of these T-cells by engaging a TCR to promote a T-cell response. It is,  
however, usually understood that certain peptides which are found to bind to MHC Class  
II molecules may be retained in a protein sequence because such peptides are recognized  
as "self" within the organism into which the final protein is administered.  
15  
It is known, that certain of these T-cell epitope peptides can be released during the  
degradation of peptides, polypeptides or proteins within cells and subsequently be  
presented by molecules of the major histocompatibility complex (MHC) in order to  
trigger the activation of T-cells. For peptides presented by MHC Class II, such activation  
20 of T-cells can then give rise, for example, to an antibody response by direct stimulation of  
B-cells to produce such antibodies.

MHC Class II molecules are a group of highly polymorphic proteins which play a central  
role in helper T-cell selection and activation. The human leukocyte antigen group DR  
25 (HLA-DR) are the predominant isotype of this group of proteins and are the major focus  
of the present invention. However, isotypes HLA-DQ and HLA-DP perform similar  
functions, hence the present invention is equally applicable to these. The MHC class II  
DR molecule is made of an alpha and a beta chain which insert at their C-termini through  
the cell membrane. Each hetero-dimer possesses a ligand binding domain which binds to  
30 peptides varying between 9 and 20 amino acids in length, although the binding groove  
can accommodate a maximum of 11 amino acids. The ligand binding domain is  
comprised of amino acids 1 to 85 of the alpha chain, and amino acids 1 to 94 of the beta  
chain. DQ molecules have recently been shown to have an homologous structure and the

DP family proteins are also expected to be very similar. In humans approximately 70 different allotypes of the DR isotype are known, for DQ there are 30 different allotypes and for DP 47 different allotypes are known. Each individual bears two to four DR alleles, two DQ and two DP alleles. The structure of a number of DR molecules has been solved and such structures point to an open-ended peptide binding groove with a number of hydrophobic pockets which engage hydrophobic residues (pocket residues) of the peptide [Brown et al *Nature* (1993) 364: 33; Stern et al (1994) *Nature* 368: 215]. Polymorphism identifying the different allotypes of class II molecule contributes to a wide diversity of different binding surfaces for peptides within the peptide binding groove and at the population level ensures maximal flexibility with regard to the ability to recognize foreign proteins and mount an immune response to pathogenic organisms. There is a considerable amount of polymorphism within the ligand binding domain with distinct "families" within different geographical populations and ethnic groups. This polymorphism affects the binding characteristics of the peptide binding domain, thus different "families" of DR molecules will have specificities for peptides with different sequence properties, although there may be some overlap. This specificity determines recognition of Th-cell epitopes (Class II T-cell response) which are ultimately responsible for driving the antibody response to B-cell epitopes present on the same protein from which the Th-cell epitope is derived. Thus, the immune response to a protein in an individual is heavily influenced by T-cell epitope recognition which is a function of the peptide binding specificity of that individual's HLA-DR allotype. Therefore, in order to identify T-cell epitopes within a protein or peptide in the context of a global population, it is desirable to consider the binding properties of as diverse a set of HLA-DR allotypes as possible, thus covering as high a percentage of the world population as possible.

25

An immune response to a therapeutic protein proceeds via the MHC class II peptide presentation pathway. Here exogenous proteins are engulfed and processed for presentation in association with MHC class II molecules of the DR, DQ or DP type. MHC Class II molecules are expressed by professional antigen presenting cells (APCs), such as macrophages and dendritic cells amongst others. Engagement of a MHC class II peptide complex by a cognate T-cell receptor on the surface of the T-cell, together with the cross-binding of certain other co-receptors such as the CD4 molecule, can induce an activated state within the T-cell. Activation leads to the release of cytokines further

activating other lymphocytes such as B cells to produce antibodies or activating T killer cells as a full cellular immune response.

The ability of a peptide to bind a given MHC class II molecule for presentation on the surface of an APC is dependent on a number of factors most notably its primary

5 sequence. This will influence both its propensity for proteolytic cleavage and also its affinity for binding within the peptide binding cleft of the MHC class II molecule. The MHC class II / peptide complex on the APC surface presents a binding face to a particular T-cell receptor (TCR) able to recognize determinants provided both by exposed residues of the peptide and the MHC class II molecule.

10

In the art there are procedures for identifying synthetic peptides able to bind MHC class II molecules (e.g. WO98/52976 and WO00/34317). Such peptides may not function as T-cell epitopes in all situations, particularly, *in vivo* due to the processing pathways or other phenomena. T-cell epitope identification is the first step to epitope elimination. The

15 identification and removal of potential T-cell epitopes from proteins has been previously disclosed. In the art methods have been provided to enable the detection of T-cell epitopes usually by computational means scanning for recognized sequence motifs in experimentally determined T-cell epitopes or alternatively using computational techniques to predict MHC class II-binding peptides and in particular DR-binding peptides.

20 WO98/52976 and WO00/34317 teach computational threading approaches to identifying polypeptide sequences with the potential to bind a sub-set of human MHC class II DR allotypes. In these teachings, predicted T-cell epitopes are removed by the use of judicious amino acid substitution within the primary sequence of the therapeutic antibody or non-antibody protein of both non-human and human derivation.

25 Other techniques exploiting soluble complexes of recombinant MHC molecules in combination with synthetic peptides and able to bind to T-cell clones from peripheral blood samples from human or experimental animal subjects have been used in the art [Kem, F. et al (1998) *Nature Medicine* 4:975-978; Kwok, W.W. et al (2001) *TRENDS in Immunol.* 22:583-588]. These and other schemes including for example the use of whole proteins or synthetic peptides or variant molecules to the protein of interest may be

screened for molecules with altered ability to bind or stimulate T-cells may equally be exploited in an epitope identification strategy.

As depicted above and as consequence thereof, it would be desirable to identify and to

5 remove or at least to reduce T-cell epitopes from a given in principal therapeutically valuable but originally immunogenic peptide, polypeptide or protein.

One of these therapeutically valuable molecules is bryodin 1. The present invention provides for modified forms of bryodin 1 with one or more T cell epitopes removed. The

10 sequence of bryodin 1 protein as given by Gawlak et al [Gawlak, S. et al (1997) *Biochemistry* 36:3095-3103] is depicted in single-letter code as follows:

DVSFRLSGATTTSYGVFIKNLREALPYERKVYNIPLLRSSISGSGRYTLLHLTNYADETI  
SVAVDVTNVYIMGYLAGDVSYFFNEASATEAAKFVFKDAKKVTLPYSGNYERLQTAAGK  
15 IRENIPLGLPALDSAITTLYYTASSAASALLVLIQSTAESARYKFIEQQIGKRVDKTFL  
PSLATISLENNWSALSQIQIASTNNQFESPVVLIDGNNQRVSITNASARVVTNSIALL  
LNRNNIAAIGEDISMTLIGFEHGLYGI

The bryodin 1 protein is single polypeptide of 267 amino acids with a molecular weight

20 of approximately 29,000 Da. Bryodin 1 is a type 1 ribosome inactivating protein (RIP) originally isolated from the roots of the plant *Bryonia dionica* [US,5541110]. There is considerable interest in this and other RIPs on account of their toxicity to living cells. In particular recombinant forms in fusion with cell-specific targeting domains (e.g. antibodies) have potential value in many therapeutic areas where the selective killing of

25 particular cell populations is a desired outcome.

It is a particular objective of the present invention to provide modified bryodin 1 proteins in which the immune characteristic is modified by means of reduced numbers of potential T-cell epitopes.

30 Others have provided bryodin molecules and in particular recombinant bryodin 1 [US,5541110; US,5932447], but these teachings do not recognise the importance of T cell epitopes to the immunogenic properties of the protein nor have been conceived to directly influence said properties in a specific and controlled way according to the scheme of the present invention.

By contrast, the PCT patent application WO00/34317 published 15-June 2000 discloses a modified bryodin 1 molecule including substitutions at positions 5,6, 18, 27, 111, 164, 216, 222, 237 and 249. The substitutions have been selected on the basis of an *in silico* motif matching tool and do not address the most biologically relevant MHC class II epitopes detected in a biological assay and which are for the first time disclosed herein.

There is a continued need for bryodin 1 analogues with enhanced properties. Desired enhancements include alternative schemes and modalities for the expression and purification of the said therapeutic, but also and especially, improvements in the biological properties of the protein. There is a particular need for enhancement of the *in vivo* characteristics when administered to the human subject. In this regard, it is highly desired to provide bryodin 1 with reduced or absent potential to induce an immune response in the human subject.

## 15 SUMMARY AND DESCRIPTION OF THE INVENTION

The present invention provides for modified forms of bryodin 1, in which the immune characteristic is modified by means of reduced or removed numbers of potential T-cell epitopes.

The invention discloses sequences identified within the bryodin 1 primary sequence that are potential T-cell epitopes by virtue of MHC class II binding potential. This disclosure specifically pertains the bryodin 1 protein being 267 amino acid residues.

The invention discloses also specific positions within the primary sequence of the molecule which according to the invention are to be altered by specific amino acid substitution, addition or deletion whilst retaining to a maximum degree the biological activity of the protein.

The invention furthermore discloses methods to produce such modified molecules, and above all methods to identify said T-cell epitopes which require alteration in order to reduce or remove immunogenic sites.

The present invention provides for modified forms of bryodin 1 proteins that are expected to display enhanced properties *in vivo*. The present invention discloses the major regions of the bryodin primary sequence that are immunogenic in man and provides modification to the said sequences to eliminate or reduce the immunogenic effectiveness of these sites. In one embodiment, synthetic peptides comprising the said immunogenic regions can be

provided in pharmaceutical composition for the purpose of promoting a tolerogenic response to the whole molecule. In a further embodiment, the modified bryodin 1 molecules of the present invention can be used in pharmaceutical compositions.

5

In summary the invention relates to the following issues:

- a modified molecule having the biological activity of bryodin 1 and being substantially non-immunogenic or less immunogenic than any non-modified molecule having the same biological activity when used *in vivo*;
- 10 • an accordingly specified molecule, wherein said loss of immunogenicity is achieved by removing one or more T-cell epitopes derived from the originally non-modified molecule;
- an accordingly specified molecule, wherein said loss of immunogenicity is achieved by reduction in numbers of MHC allotypes able to bind peptides derived from said molecule;
- 15 • an accordingly specified molecule, wherein one T-cell epitope is removed; an accordingly specified molecule, wherein said originally present T-cell epitopes are MHC class II ligands or peptide sequences which show the ability to stimulate or bind T-cells via presentation on class II;
- an accordingly specified molecule, wherein said peptide sequences are selected from the group as depicted in FIGURE 1;
- 20 • an accordingly specified molecule, wherein 1 – 9 amino acid residues, preferably one amino acid residue in any of the originally present T-cell epitopes are altered; an accordingly specified molecule, wherein the alteration of the amino acid residues is substitution, addition or deletion of originally present amino acid(s) residue(s) by other amino acid residue(s) at specific position(s);
- 25 • an accordingly specified molecule, wherein, if necessary, additionally further alteration usually by substitution, addition or deletion of specific amino acid(s) is conducted to restore biological activity of said molecule;
- a peptide molecule of above sharing greater than 90% amino acid identity with any of the peptide sequences of FIGURE 1;
- 30 • a peptide molecule of above sharing greater than 80% amino acid identity with any of the peptide sequences of FIGURE 1;

- peptide sequences as above able to bind MHC class II;
- an accordingly specified bryodin 1 molecule, wherein one or more of the amino acid substitutions is conducted at a position corresponding to any of the amino acids specified within FIGURE 1;

5     • an accordingly specified molecule wherein alteration is conducted at one or more residues from any or all of the string of contiguous residues of sequences (a), (b), (c), (d), or (e) as below wherein said sequences are derived from the bryodin 1 wild-type sequence where using single letter code;

10     (a) = ITTLYYYYTASSAASALLVLIQSTAESA,  
       (b) = ATEAAKFKVFKDAKKK,  
       (c) = ERLQTAAGKIRENIPPLGLPALS,DA,  
       (d) = ITTLYYYYTASSAASALLVLIQSTAESA,  
       (e) = TFLPSLATISLENNWSALSQIQIAST,

- a peptide molecule comprising 13–15 consecutive residues from any of sequences (a), (b), (c), (d) or (e) above;
- a peptide molecule comprising at least 9 consecutive residues from any of the sequences (a), (b), (c) (d) or (e) above;
- a peptide molecule of above sharing greater than 90% amino acid identity with any of the peptide sequences derived from (a), (b), (d) or (e) above;
- 20     • a peptide molecule of above sharing greater than 80% amino acid identity with any of the peptide sequences derived from (a), (b), (c) (d) or (e) above;
- peptide sequences as above able to bind MHC class II;
- an accordingly specified bryodin 1 molecule, wherein one or more of the amino acid substitutions is conducted at a position corresponding to any of the amino acids specified within any of sequences (a), (b), (c), (d) or (e) above;
- 25     • an accordingly specified bryodin 1 molecule, wherein one or more of the amino acid substitutions is conducted at a position corresponding to any of the amino acids specified within sequence (b) above;
- 30     • a peptide sequence consisting of at least 9 consecutive amino acid residues of any of the sequences (a), (b), (c), (d) or (e) as specified above and its use for the manufacture of bryodin 1,  $\alpha$ -trichosanthin,  $\alpha$ -momorcharin or  $\beta$ -momorcharin having substantially no or less immunogenicity than any non-modified molecule and having the biological activity of a type 1 RIP when used *in vivo*;

- a pharmaceutical composition comprising any of the peptides or modified peptides of above having the activity of binding to MHC class II;
- a DNA sequence or molecule which codes for any of said specified modified molecules as defined above and below;

5     • a pharmaceutical composition comprising a modified molecule having the biological activity of bryodin 1;

- a pharmaceutical composition as defined above and / or in the claims, optionally together with a pharmaceutically acceptable carrier, diluent or excipient;
- a method for manufacturing a modified molecule having the biological activity of

10    bryodin 1 as defined in any of the claims of the above-cited claims comprising the following steps: (i) determining the amino acid sequence of the polypeptide or part thereof; (ii) identifying one or more potential T-cell epitopes within the amino acid sequence of the protein by any method including determination of the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays;

15    (iii) designing new sequence variants with one or more amino acids within the identified potential T-cell epitopes modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope as determined by the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays; (iv) constructing such sequence variants by recombinant DNA techniques and testing said variants in order to identify one or more variants with desirable properties; and (v) optionally repeating steps (ii) – (iv);

20    • an accordingly specified method, wherein step (iii) is carried out by substitution, addition or deletion of 1 – 9 amino acid residues in any of the originally present T-cell epitopes;

25    • an accordingly specified method, wherein the alteration is made with reference to an homologous protein sequence and / or *in silico* modeling techniques;

- an accordingly specified method, wherein step (ii) of above is carried out by the following steps: (a) selecting a region of the peptide having a known amino acid residue sequence; (b) sequentially sampling overlapping amino acid residue segments of predetermined uniform size and constituted by at least three amino acid residues from the selected region; (c) calculating MHC Class II molecule binding score for each said sampled segment by summing assigned values for each hydrophobic amino acid residue side chain present in said sampled amino acid residue segment; and (d)

identifying at least one of said segments suitable for modification, based on the calculated MHC Class II molecule binding score for that segment, to change overall MHC Class II binding score for the peptide without substantially reducing therapeutic utility of the peptide; step (c) is preferably carried out by using a Böhm scoring function modified to include 12-6 van der Waal's ligand-protein energy repulsive term and ligand conformational energy term by (1) providing a first data base of MHC Class II molecule models; (2) providing a second data base of allowed peptide backbones for said MHC Class II molecule models; (3) selecting a model from said first data base; (4) selecting an allowed peptide backbone from said second data base; (5) identifying amino acid residue side chains present in each sampled segment; (6) determining the binding affinity value for all side chains present in each sampled segment; and repeating steps (1) through (5) for each said model and each said backbone;

- a 13mer T-cell epitope peptide having a potential MHC class II binding activity and created from non-modified bryodin 1, selected from the group as depicted in FIGURE 1 and its use for the manufacture of bryodin 1 having substantially no or less immunogenicity than any non-modified molecule with the same biological activity when used *in vivo*;
- a peptide sequence consisting of at least 9 consecutive amino acid residues of a 13mer T-cell epitope peptide as specified above and its use for the manufacture of bryodin 1 having substantially no or less immunogenicity than any non-modified molecule and having the biological activity of bryodin 1 when used *in vivo*;
- a 13mer T-cell epitope peptide having a potential MHC class II binding activity and created from non-modified bryodin 1, selected from any of the group of sequences (FIGURE 1) and its use for the manufacture of bryodin 1 having substantially no or less immunogenicity than any non-modified molecule and having the biological activity of a bryodin 1 molecule when used *in vivo*;
- a peptide sequence consisting of at least 9 consecutive amino acid residues of a 13mer T-cell epitope peptide as derived from any of the sequences in FIGURE 1 and its use for the manufacture of bryodin 1 having substantially no or less immunogenicity than any non-modified molecule and having the biological activity of a bryodin molecule when used *in vivo*.

The term "T-cell epitope" means according to the understanding of this invention an amino acid sequence which is able to bind MHC class II, able to stimulate T-cells and / or also to bind (without necessarily measurably activating) T-cells in complex with MHC class II.

5 The term "peptide" as used herein and in the appended claims, is a compound that includes two or more amino acids. The amino acids are linked together by a peptide bond (defined herein below). There are 20 different naturally occurring amino acids involved in the biological production of peptides, and any number of them may be linked in any order to form a peptide chain or ring. The naturally occurring amino acids employed in

10 the biological production of peptides all have the L-configuration. Synthetic peptides can be prepared employing conventional synthetic methods, utilizing L-amino acids, D-amino acids, or various combinations of amino acids of the two different configurations. Some peptides contain only a few amino acid units. Short peptides, e.g., having less than ten amino acid units, are sometimes referred to as "oligopeptides". Other peptides contain a

15 large number of amino acid residues, e.g. up to 100 or more, and are referred to as "polypeptides". By convention, a "polypeptide" may be considered as any peptide chain containing three or more amino acids, whereas a "oligopeptide" is usually considered as a particular type of "short" polypeptide. Thus, as used herein, it is understood that any reference to a "polypeptide" also includes an oligopeptide. Further, any reference to a

20 "peptide" includes polypeptides, oligopeptides, and proteins. Each different arrangement of amino acids forms different polypeptides or proteins. The number of polypeptides—and hence the number of different proteins—that can be formed is practically unlimited.

"Alpha carbon (C $\alpha$ )" is the carbon atom of the carbon-hydrogen (CH) component that is in the peptide chain. A "side chain" is a pendant group to C $\alpha$  that can comprise a simple

25 or complex group or moiety, having physical dimensions that can vary significantly compared to the dimensions of the peptide.

The invention may be applied to any bryodin 1 species of molecule with substantially the same primary amino acid sequences as those disclosed herein and would include therefore bryodin 1 molecules derived by genetic engineering means or other processes and may

30 contain more or less than 267 amino acid residues.

The invention is conceived to overcome the practical reality that soluble proteins introduced with therapeutic intent in man trigger an immune response resulting in

development of host antibodies that bind to the soluble protein. The present invention seeks to address this by providing bryodin 1 proteins with altered propensity to elicit an immune response on administration to the human host. According to the methods described herein, the inventors have discovered the regions of the bryodin 1 molecule comprising the critical T-cell epitopes driving the immune responses to this protein.

The general method of the present invention leading to the modified bryodin 1 comprises the following steps:

- (a) determining the amino acid sequence of the polypeptide or part thereof;
- 10 (b) identifying one or more potential T-cell epitopes within the amino acid sequence of the protein by any method including determination of the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays;
- (c) designing new sequence variants with one or more amino acids within the identified potential T-cell epitopes modified in such a way to substantially reduce or eliminate the 15 activity of the T-cell epitope as determined by the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays. Such sequence variants are created in such a way to avoid creation of new potential T-cell epitopes by the sequence variations unless such new potential T-cell epitopes are, in turn, modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope; and
- 20 (d) constructing such sequence variants by recombinant DNA techniques and testing said variants in order to identify one or more variants with desirable properties according to well known recombinant techniques.

The identification of potential T-cell epitopes according to step (b) can be carried out 25 according to methods described previously in the prior art. Suitable methods are disclosed in WO 98/59244; WO 98/52976; WO 00/34317 and may preferably be used to identify binding propensity of FVIII-derived peptides to an MHC class II molecule.

In practice a number of variant bryodin proteins will be produced and tested for the 30 desired immune and functional characteristic. The variant proteins will most preferably be produced by recombinant DNA techniques although other procedures including chemical synthesis of bryodin 1 fragments may be contemplated.

The results of an analysis according to step (b) of the above scheme and pertaining to the bryodin 1 protein sequence is presented in FIGURE 1.

The invention relates to bryodin analogues in which substitutions of at least one amino acid residue have been made at positions resulting in a substantial reduction in activity of or elimination of one or more potential T-cell epitopes from the protein. One or more amino acid substitutions at particular points within any of the potential MHC class II ligands identified in FIGURE 1 may result in a bryodin molecule with a reduced immunogenic potential when administered as a therapeutic to the human host.

10

It is most preferred to provide a bryodin 1 molecule in which amino acid modification (e.g. a substitution) is conducted within the most immunogenic regions of the parent molecule. The major preferred embodiments of the present invention comprise bryodin 1 molecules for which any of the MHC class II ligands of FIGURE 1 are altered such as to 15 eliminate binding or otherwise reduce the numbers of MHC allotypes to which the peptide can bind.

It is most preferred to provide a bryodin 1 molecule in which amino acid modification (e.g. a substitution) is conducted within the most immunogenic regions of the parent molecule. The inventors herein have discovered that the most immunogenic regions of 20 the bryodin 1 molecule in man are confined to at least five regions R1 – R5 encompassing residues 46-66; 88-102; 112-135; 136-162 and 178-204 comprising respectively amino acid sequences; R1) RYTLHLINYADETISVAVDV; R2) ATEAAKFVFKDAKKK; R3) ERLQTAAGKIRENIPLGLPALDSA; R4) ITLYYYTASSAASALLVLIQSTAESA and R5) TFLPSLATISLENNWSALSKQIQIAST. The major preferred embodiments of 25 the present invention comprise bryodin 1 molecules for which the MHC class II ligands of FIGURE 1 and which align either in their entirety or to a minimum of 9 amino acid residues with any of the above sequence elements (R1 – R5) are altered such as to eliminate binding or otherwise reduce the numbers of MHC allotypes to which the peptide can bind.

30

For the elimination of T-cell epitopes, amino acid substitutions are preferably made at appropriate points within the peptide sequence predicted to achieve substantial reduction or elimination of the activity of the T-cell epitope. In practice an appropriate point will

preferably equate to an amino acid residue binding within one of the pockets provided within the MHC class II binding groove.

It is most preferred to alter binding within the first pocket of the cleft at the so-called P1 or P1 anchor position of the peptide. The quality of binding interaction between the P1 anchor residue of the peptide and the first pocket of the MHC class II binding groove is recognized as being a major determinant of overall binding affinity for the whole peptide. An appropriate substitution at this position of the peptide will be for a residue less readily accommodated within the pocket, for example, substitution to a more hydrophilic residue.

10 Amino acid residues in the peptide at positions equating to binding within other pocket regions within the MHC binding cleft are also considered and fall under the scope of the present.

It is understood that single amino acid substitutions within a given potential T-cell epitope are the most preferred route by which the epitope may be eliminated. Combinations of substitution within a single epitope may be contemplated and for example can be particularly appropriate where individually defined epitopes are in overlap with each other. Moreover, amino acid substitutions either singly within a given epitope or in combination within a single epitope may be made at positions not equating to the "pocket residues" with respect to the MHC class II binding groove, but at any point within the peptide sequence. Substitutions may be made with reference to an homologues structure or structural method produced using *in silico* techniques known in the art and may be based on known structural features of the molecule according to this invention. All such substitutions fall within the scope of the present invention.

25 Amino acid substitutions other than within the peptides identified above may be contemplated particularly when made in combination with substitution(s) made within a listed peptide. For example a change may be contemplated to restore structure or biological activity of the variant molecule. Such compensatory changes and changes to 30 include deletion or addition of particular amino acid residues from the bryodin 1 polypeptide resulting in a variant with desired activity and in combination with changes in any of the disclosed peptides fall under the scope of the present.

In as far as this invention relates to modified bryodin 1, compositions containing such modified bryodin proteins or fragments of modified bryodin proteins and related compositions should be considered within the scope of the invention. In another aspect, the present invention relates to nucleic acids encoding modified bryodin entities. In a 5 further aspect the present invention relates to methods for therapeutic treatment of humans using the modified bryodin 1 proteins. In this aspect the modified bryodin 1 protein may be linked with an antibody molecule or fragment of an antibody molecule. The linkage may be by means of a chemical cross-linker or the bryodin 1-antibody may be produced as a recombinant fusion protein. The fusion molecule may contain the 10 modified bryodin 1 domain with antibody domain orientated towards the N-terminus of the fusion molecule although the opposite orientation may be contemplated.

Desired antibody specificities for linkage to the modified bryodin 1 molecule of the present include those directed towards internalising antigen determinants. Examples of 15 this class of antigen are rare but would include the A33 antigen [Heath, J.K. et al (1997) *Proc. Natl. Acad. Sci. U.S.A.* 94: 469-474] and the GA733-1 antigen [US,5,840,854]. The carcinoembryonic antigen may also be contemplated for use and may be targeted by any of numerous antibodies but may include MFE23 [Chester, K.A. et al (1994) *Lancet* 343: 455], A5B7 [WO92/010159], T84.66 [US,5,081,235] MN-14 [Hansen, H.J. et al (1993) 20 *Cancer* 71: 3478-3485], COL-1 [US,5,472,693] and others. Other desired specificities include antibodies directed to non-internalising antigens and this may include antigens such as the 40kDa glycoprotein antigen as recognised by antibody KS1/4 [Spearman et al (1987) *J. Pharmacol. Exp. Therapeutics* 241: 695-703] and other antibodies. Other 25 antigens such as the epidermal growth factor receptor (HER1) or related receptors such as HER2 may be selected including anti-GD2 antibodies such as antibody 14.18 [US,4,675,287; EP 0 192 657], or antibodies to the prostate specific membrane antigen [US,6,107,090], the IL-2 receptor [US,6,013,256], the A33 antigen the Lewis Y determinant, mucin glycoproteins or others may be contemplated.

30 In all instances where a modified bryodin 1 protein is made in fusion with an antibody sequence it is most desired to use antibody sequences in which T cell epitopes or sequences able to bind MHC class II molecules or stimulate T cells or bind to T cells in association with MHC class II molecules have been removed.

A further embodiment of the present invention, the modified bryodin 1 protein may be linked to a non-antibody protein yet a protein able to direct a specific binding interaction to a particular target cell. Such protein moieties include a variety of polypeptide ligands 5 for which there are specific cell surface receptors and include therefore numerous cytokines, peptide and polypeptide hormones and other biological response modifiers. Prominent examples include such proteins as vascular epithelial growth factor, epidermal 10 growth factor, heregulin, the interleukins, interferons, tumour necrosis factor and other protein and glycoprotein molecules. Fusion proteins of these and other molecules with bryodin 1 of the present invention may be contemplated and may comprise the modified bryodin 1 moiety in either the N-terminal or C-terminal orientation with respect to the protein ligand domain. Equally, chemical cross-linking of the purified ligand to the modified bryodin 1 protein may be contemplated and within the scope of the present 15 invention.

15 In a further embodiment the modified bryodin 1 protein of the present may be used as a complex containing a water soluble polymer such as hydroxypropylmethacrylamide or other polymers where the modified bryodin 1 protein is in covalent attachment to the polymer or in a non-covalent binding interaction with the polymer. Such an embodiment 20 may additionally include an antigen binding domain such as an antibody or a fragment of an antibody in combination with the polymer bryodin 1 complex.

In a further aspect still, the invention relates to methods for therapeutic treatment using pharmaceutical preparations comprising peptide or derivative molecules with sequence 25 identity or part identity with the sequences herein disclosed.

In a yet further aspect, the major immunogenic epitopes herein disclosed and relating to the bryodin 1 molecule are also shown herein to be present within the primary sequence of a number of other type 1 RIP proteins of which bryodin 1 is an example. Thus the 30 proteins  $\alpha$ -trichosanthin (1TCS),  $\alpha$ -momorcharin (1MOM) and  $\beta$ -momorcharin (1CF5) and others may be shown by protein sequence analysis to contain sequence elements with identity or near identity to the immunogenic regions of the bryodin 1 molecule. FIGURE 3 depicts sequence comparisons between bryodin 1 major epitopes and sequence elements from 1TCS, 1MOM and 1CF5 proteins. The present invention in so far as it relates to

peptides and modified sequences derived from the bryodin 1 protein, where the identical or substantially similar sequences are identified within other proteins, these are considered equally to fall under the scope of the present.

5 The invention will now be illustrated by the following figures:

FIGURE 1 provides a list of peptide sequences in bryodin 1 with potential human MHC class II binding activity. Peptides are 13-mers, amino acids are identified using single letter code

10

FIGURE 2 provides a table of the bryodin 1 15-mer peptide sequences analysed using the naïve human *in vitro* T-cell assay of EXAMPLE 2. The peptide ID# and position of the N-terminal peptide residue within the bryodin 1 sequence is indicated

15

20

FIGURE 3 indicates the sequence elements R1, R2, R3, R4 and R5 from the bryodin 1 (1BRY) sequence which give a stimulation index of 2.0 or greater in the naïve human *in vitro* T-cell assay of EXAMPLE 2. Corresponding sequences from related proteins  $\alpha$ -trichosanthin (1TCS),  $\alpha$ -momorcharin (1MOM) and  $\beta$ -momorcharin (1CF5) are shown beneath each bryodin 1 sequence. Sequences are identical to bryodin 1 except where indicated. Amino acids are depicted using single letter code.


25

### EXAMPLE 1

There are a number of factors that play important roles in determining the total structure of a protein or polypeptide. First, the peptide bond, i.e., that bond which joins the amino acids in the chain together, is a covalent bond. This bond is planar in structure,

30 essentially a substituted amide. An "amide" is any of a group of organic compounds containing the grouping -CONH-.

The planar peptide bond linking C $\alpha$  of adjacent amino acids may be represented as depicted below:



Because the O=C and the C-N atoms lie in a relatively rigid plane, free rotation does not occur about these axes. Hence, a plane schematically depicted by the interrupted line is sometimes referred to as an "amide" or "peptide plane" plane wherein lie the oxygen (O), carbon (C), nitrogen (N), and hydrogen (H) atoms of the peptide backbone. At opposite corners of this amide plane are located the C<sub>α</sub> atoms. Since there is substantially no rotation about the O=C and C-N atoms in the peptide or amide plane, a polypeptide chain thus comprises a series of planar peptide linkages joining the C<sub>α</sub> atoms.

A second factor that plays an important role in defining the total structure or conformation of a polypeptide or protein is the angle of rotation of each amide plane about the common C<sub>α</sub> linkage. The terms "angle of rotation" and "torsion angle" are hereinafter regarded as equivalent terms. Assuming that the O, C, N, and H atoms remain in the amide plane (which is usually a valid assumption, although there may be some slight deviations from planarity of these atoms for some conformations), these angles of rotation define the N and R polypeptide's backbone conformation, i.e., the structure as it exists between adjacent residues. These two angles are known as  $\phi$  and  $\psi$ . A set of the angles  $\phi_i, \psi_i$ , where the subscript i represents a particular residue of a polypeptide chain, thus effectively defines the polypeptide secondary structure. The conventions used in defining the  $\phi, \psi$  angles, i.e., the reference points at which the amide planes form a zero degree angle, and the definition of which angle is  $\phi$ , and which angle is  $\psi$ , for a given polypeptide, are defined in the literature. See, e.g., Ramachandran et al. *Adv. Prot. Chem.* 23:283-437 (1968), at pages 285-94, which pages are incorporated herein by reference.

The present method can be applied to any protein, and is based in part upon the discovery that in humans the primary Pocket 1 anchor position of MHC Class II molecule binding grooves has a well designed specificity for particular amino acid side chains. The specificity of this pocket is determined by the identity of the amino acid at position 86 of the beta chain of the MHC Class II molecule. This site is located at the bottom of Pocket 1 and determines the size of the side chain that can be accommodated by this pocket. Marshall, K. W., *J. Immunol.*, 152:4946-4956 (1994). If this residue is a glycine, then all

hydrophobic aliphatic and aromatic amino acids (hydrophobic aliphatics being: valine, leucine, isoleucine, methionine and aromatics being: phenylalanine, tyrosine and tryptophan) can be accommodated in the pocket, a preference being for the aromatic side chains. If this pocket residue is a valine, then the side chain of this amino acid protrudes 5 into the pocket and restricts the size of peptide side chains that can be accommodated such that only hydrophobic aliphatic side chains can be accommodated. Therefore, in an amino acid residue sequence, wherever an amino acid with a hydrophobic aliphatic or aromatic side chain is found, there is the potential for a MHC Class II restricted T-cell epitope to be present. If the side-chain is hydrophobic aliphatic, however, it is 10 approximately twice as likely to be associated with a T-cell epitope than an aromatic side chain (assuming an approximately even distribution of Pocket 1 types throughout the global population).

A computational method embodying the present invention profiles the likelihood of peptide regions to contain T-cell epitopes as follows:

15 (1) The primary sequence of a peptide segment of predetermined length is scanned, and all hydrophobic aliphatic and aromatic side chains present are identified. (2) The hydrophobic aliphatic side chains are assigned a value greater than that for the aromatic side chains; preferably about twice the value assigned to the aromatic side chains, e.g., a value of 2 for a hydrophobic aliphatic side chain and a value of 1 for an aromatic side 20 chain. (3) The values determined to be present are summed for each overlapping amino acid residue segment (window) of predetermined uniform length within the peptide, and the total value for a particular segment (window) is assigned to a single amino acid residue at an intermediate position of the segment (window), preferably to a residue at about the midpoint of the sampled segment (window). This procedure is repeated for 25 each sampled overlapping amino acid residue segment (window). Thus, each amino acid residue of the peptide is assigned a value that relates to the likelihood of a T-cell epitope being present in that particular segment (window). (4) The values calculated and assigned as described in Step 3, above, can be plotted against the amino acid coordinates of the entire amino acid residue sequence being assessed. (5) All portions of the sequence which 30 have a score of a predetermined value, e.g., a value of 1, are deemed likely to contain a T-cell epitope and can be modified, if desired.

This particular aspect of the present invention provides a general method by which the regions of peptides likely to contain T-cell epitopes can be described. Modifications to the

peptide in these regions have the potential to modify the MHC Class II binding characteristics.

According to another aspect of the present invention, T-cell epitopes can be predicted with greater accuracy by the use of a more sophisticated computational method which 5 takes into account the interactions of peptides with models of MHC Class II alleles. The computational prediction of T-cell epitopes present within a peptide according to this particular aspect contemplates the construction of models of at least 42 MHC Class II alleles based upon the structures of all known MHC Class II molecules and a method for the use of these models in the computational identification of T-cell epitopes, the 10 construction of libraries of peptide backbones for each model in order to allow for the known variability in relative peptide backbone alpha carbon (C<sub>α</sub>) positions, the construction of libraries of amino-acid side chain conformations for each backbone dock with each model for each of the 20 amino-acid alternatives at positions critical for the 15 interaction between peptide and MHC Class II molecule, and the use of these libraries of backbones and side-chain conformations in conjunction with a scoring function to select the optimum backbone and side-chain conformation for a particular peptide docked with a particular MHC Class II molecule and the derivation of a binding score from this interaction.

Models of MHC Class II molecules can be derived via homology modeling from a 20 number of similar structures found in the Brookhaven Protein Data Bank ("PDB"). These may be made by the use of semi-automatic homology modeling software (Modeller, Sali 25 A. & Blundell TL., 1993. *J. Mol Biol* 234:779-815) which incorporates a simulated annealing function, in conjunction with the CHARMM force-field for energy minimisation (available from Molecular Simulations Inc., San Diego, Ca.). Alternative modeling methods can be utilized as well.

The present method differs significantly from other computational methods which use 30 libraries of experimentally derived binding data of each amino-acid alternative at each position in the binding groove for a small set of MHC Class II molecules (Marshall, K.W., et al., *Biomed. Pept. Proteins Nucleic Acids*, 1(3):157-162) (1995) or yet other computational methods which use similar experimental binding data in order to define the binding characteristics of particular types of binding pockets within the groove, again using a relatively small subset of MHC Class II molecules, and then 'mixing and matching' pocket types from this pocket library to artificially create further 'virtual' .

MHC Class II molecules (Stuiniolo T., et al., *Nat. Biotech.*, **17**(6): 555-561 (1999). Both prior methods suffer the major disadvantage that, due to the complexity of the assays and the need to synthesize large numbers of peptide variants, only a small number of MHC Class II molecules can be experimentally scanned. Therefore the first prior method can

5 only make predictions for a small number of MHC Class II molecules. The second prior method also makes the assumption that a pocket lined with similar amino-acids in one molecule will have the same binding characteristics when in the context of a different Class II allele and suffers further disadvantages in that only those MHC Class II molecules can be 'virtually' created which contain pockets contained within the pocket

10 library. Using the modeling approach described herein, the structure of any number and type of MHC Class II molecules can be deduced, therefore alleles can be specifically selected to be representative of the global population. In addition, the number of MHC Class II molecules scanned can be increased by making further models further than having to generate additional data via complex experimentation.

15 The use of a backbone library allows for variation in the positions of the C $\alpha$  atoms of the various peptides being scanned when docked with particular MHC Class II molecules. This is again in contrast to the alternative prior computational methods described above which rely on the use of simplified peptide backbones for scanning amino-acid binding in particular pockets. These simplified backbones are not likely to be representative of

20 backbone conformations found in 'real' peptides leading to inaccuracies in prediction of peptide binding. The present backbone library is created by superposing the backbones of all peptides bound to MHC Class II molecules found within the Protein Data Bank and noting the root mean square (RMS) deviation between the C $\alpha$  atoms of each of the eleven amino-acids located within the binding groove. While this library can be derived from a

25 small number of suitable available mouse and human structures (currently 13), in order to allow for the possibility of even greater variability, the RMS figure for each C"- $\alpha$  position is increased by 50%. The average C $\alpha$  position of each amino-acid is then determined and a sphere drawn around this point whose radius equals the RMS deviation at that position plus 50%. This sphere represents all allowed C $\alpha$  positions.

30 Working from the C $\alpha$  with the least RMS deviation (that of the amino-acid in Pocket 1 as mentioned above, equivalent to Position 2 of the 11 residues in the binding groove), the sphere is three-dimensionally gridded, and each vertex within the grid is then used as a possible location for a C $\alpha$  of that amino-acid. The subsequent amide plane, corresponding

to the peptide bond to the subsequent amino-acid is grafted onto each of these  $\text{C}\alpha$ s and the  $\phi$  and  $\psi$  angles are rotated step-wise at set intervals in order to position the subsequent  $\text{C}\alpha$ . If the subsequent  $\text{C}\alpha$  falls within the 'sphere of allowed positions' for this  $\text{C}\alpha$  than the orientation of the dipeptide is accepted, whereas if it falls outside the sphere then the 5 dipeptide is rejected.

This process is then repeated for each of the subsequent  $\text{C}\alpha$  positions, such that the peptide grows from the Pocket 1  $\text{C}\alpha$  'seed', until all nine subsequent  $\text{C}\alpha$ s have been positioned from all possible permutations of the preceding  $\text{C}\alpha$ s. The process is then repeated once more for the single  $\text{C}\alpha$  preceding pocket 1 to create a library of backbone 10  $\text{C}\alpha$  positions located within the binding groove.

The number of backbones generated is dependent upon several factors: The size of the 'spheres of allowed positions'; the fineness of the gridding of the 'primary sphere' at the Pocket 1 position; the fineness of the step-wise rotation of the  $\phi$  and  $\psi$  angles used to position subsequent  $\text{C}\alpha$ s. Using this process, a large library of backbones can be created. 15 The larger the backbone library, the more likely it will be that the optimum fit will be found for a particular peptide within the binding groove of an MHC Class II molecule. Inasmuch as all backbones will not be suitable for docking with all the models of MHC Class II molecules due to clashes with amino-acids of the binding domains, for each allele 20 a subset of the library is created comprising backbones which can be accommodated by that allele.

The use of the backbone library, in conjunction with the models of MHC Class II molecules creates an exhaustive database consisting of allowed side chain conformations for each amino-acid in each position of the binding groove for each MHC Class II molecule docked with each allowed backbone. This data set is generated using a simple 25 steric overlap function where a MHC Class II molecule is docked with a backbone and an amino-acid side chain is grafted onto the backbone at the desired position. Each of the rotatable bonds of the side chain is rotated step-wise at set intervals and the resultant positions of the atoms dependent upon that bond noted. The interaction of the atom with atoms of side-chains of the binding groove is noted and positions are either accepted or 30 rejected according to the following criteria: The sum total of the overlap of all atoms so far positioned must not exceed a pre-determined value. Thus the stringency of the conformational search is a function of the interval used in the step-wise rotation of the

bond and the pre-determined limit for the total overlap. This latter value can be small if it is known that a particular pocket is rigid, however the stringency can be relaxed if the positions of pocket side-chains are known to be relatively flexible. Thus allowances can be made to imitate variations in flexibility within pockets of the binding groove. This 5 conformational search is then repeated for every amino-acid at every position of each backbone when docked with each of the MHC Class II molecules to create the exhaustive database of side-chain conformations.

A suitable mathematical expression is used to estimate the energy of binding between 10 models of MHC Class II molecules in conjunction with peptide ligand conformations which have to be empirically derived by scanning the large database of backbone/side-chain conformations described above. Thus a protein is scanned for potential T-cell epitopes by subjecting each possible peptide of length varying between 9 and 20 amino-acids (although the length is kept constant for each scan) to the following computations: An MHC Class II molecule is selected together with a peptide backbone allowed for that 15 molecule and the side-chains corresponding to the desired peptide sequence are grafted on. Atom identity and interatomic distance data relating to a particular side-chain at a particular position on the backbone are collected for each allowed conformation of that amino-acid (obtained from the database described above). This is repeated for each side-chain along the backbone and peptide scores derived using a scoring function. The best 20 score for that backbone is retained and the process repeated for each allowed backbone for the selected model. The scores from all allowed backbones are compared and the highest score is deemed to be the peptide score for the desired peptide in that MHC Class II model. This process is then repeated for each model with every possible peptide 25 derived from the protein being scanned, and the scores for peptides versus models are displayed.

In the context of the present invention, each ligand presented for the binding affinity calculation is an amino-acid segment selected from a peptide or protein as discussed above. Thus, the ligand is a selected stretch of amino acids about 9 to 20 amino acids in length derived from a peptide, polypeptide or protein of known sequence. The terms 30 "amino acids" and "residues" are hereinafter regarded as equivalent terms.

The ligand, in the form of the consecutive amino acids of the peptide to be examined grafted onto a backbone from the backbone library, is positioned in the binding cleft of an MHC Class II molecule from the MHC Class II molecule model library via the

coordinates of the C"- $\alpha$  atoms of the peptide backbone and an allowed conformation for each side-chain is selected from the database of allowed conformations. The relevant atom identities and interatomic distances are also retrieved from this database and used to calculate the peptide binding score. Ligands with a high binding affinity for the MHC

5 Class II binding pocket are flagged as candidates for site-directed mutagenesis. Amino-acid substitutions are made in the flagged ligand (and hence in the protein of interest) which is then retested using the scoring function in order to determine changes which reduce the binding affinity below a predetermined threshold value. These changes can then be incorporated into the protein of interest to remove T-cell epitopes.

10 Binding between the peptide ligand and the binding groove of MHC Class II molecules involves non-covalent interactions including, but not limited to: hydrogen bonds, electrostatic interactions, hydrophobic (lipophilic) interactions and Van der Walls interactions. These are included in the peptide scoring function as described in detail below.

15 It should be understood that a hydrogen bond is a non-covalent bond which can be formed between polar or charged groups and consists of a hydrogen atom shared by two other atoms. The hydrogen of the hydrogen donor has a positive charge where the hydrogen acceptor has a partial negative charge. For the purposes of peptide/protein interactions, hydrogen bond donors may be either nitrogens with hydrogen attached or hydrogens attached to oxygen or nitrogen. Hydrogen bond acceptor atoms may be oxygens not attached to hydrogen, nitrogens with no hydrogens attached and one or two connections, or sulphurs with only one connection. Certain atoms, such as oxygens attached to hydrogens or imine nitrogens (e.g. C=NH) may be both hydrogen acceptors or donors. Hydrogen bond energies range from 3 to 7 Kcal/mol and are much stronger than Van der

20 Waal's bonds, but weaker than covalent bonds. Hydrogen bonds are also highly directional and are at their strongest when the donor atom, hydrogen atom and acceptor atom are co-linear.

25 Electrostatic bonds are formed between oppositely charged ion pairs and the strength of the interaction is inversely proportional to the square of the distance between the atoms according to Coulomb's law. The optimal distance between ion pairs is about 2.8 $\text{\AA}$ . In protein/peptide interactions, electrostatic bonds may be formed between arginine, histidine or lysine and aspartate or glutamate. The strength of the bond will depend upon

the pKa of the ionizing group and the dielectric constant of the medium although they are approximately similar in strength to hydrogen bonds.

Lipophilic interactions are favorable hydrophobic-hydrophobic contacts that occur between the protein and peptide ligand. Usually, these will occur between hydrophobic 5 amino acid side chains of the peptide buried within the pockets of the binding groove such that they are not exposed to solvent. Exposure of the hydrophobic residues to solvent is highly unfavorable since the surrounding solvent molecules are forced to hydrogen bond with each other forming cage-like clathrate structures. The resultant decrease in entropy is highly unfavorable. Lipophilic atoms may be sulphurs which are neither polar 10 nor hydrogen acceptors and carbon atoms which are not polar.

Van der Waal's bonds are non-specific forces found between atoms which are 3-4 Å apart. They are weaker and less specific than hydrogen and electrostatic bonds. The distribution of electronic charge around an atom changes with time and, at any instant, the charge 15 distribution is not symmetric. This transient asymmetry in electronic charge induces a similar asymmetry in neighboring atoms. The resultant attractive forces between atoms reaches a maximum at the Van der Waal's contact distance but diminishes very rapidly at about 1 Å to about 2 Å. Conversely, as atoms become separated by less than the contact distance, increasingly strong repulsive forces become dominant as the outer electron clouds of the atoms overlap. Although the attractive forces are relatively weak compared 20 to electrostatic and hydrogen bonds (about 0.6 Kcal/mol), the repulsive forces in particular may be very important in determining whether a peptide ligand may bind successfully to a protein.

In one embodiment, the Böhm scoring function (SCORE1 approach) is used to estimate the binding constant. (Böhm, H.J., *J. Comput Aided Mol. Des.*, 8(3):243-256 (1994), 25 which is hereby incorporated in its entirety). In another embodiment, the scoring function (SCORE2 approach) is used to estimate the binding affinities as an indicator of a ligand containing a T-cell epitope (Böhm, H.J., *J. Comput Aided Mol. Des.*, 12(4):309-323 (1998) which is hereby incorporated in its entirety). However, the Böhm scoring functions as described in the above references are used to estimate the binding affinity of 30 a ligand to a protein where it is already known that the ligand successfully binds to the protein and the protein/ligand complex has had its structure solved, the solved structure being present in the Protein Data Bank ("PDB"). Therefore, the scoring function has been developed with the benefit of known positive binding data. In order to allow for

26 / 38

discrimination between positive and negative binders, a repulsion term must be added to the equation. In addition, a more satisfactory estimate of binding energy is achieved by computing the lipophilic interactions in a pairwise manner rather than using the area based energy term of the above Böhm functions.

5 Therefore, in a preferred embodiment, the binding energy is estimated using a modified Böhm scoring function. In the modified Böhm scoring function, the binding energy between protein and ligand ( $\Delta G_{bind}$ ) is estimated considering the following parameters: The reduction of binding energy due to the overall loss of translational and rotational entropy of the ligand ( $\Delta G_0$ ); contributions from ideal hydrogen bonds ( $\Delta G_{hb}$ ) where at 10 least one partner is neutral; contributions from unperturbed ionic interactions ( $\Delta G_{ionic}$ ); lipophilic interactions between lipophilic ligand atoms and lipophilic acceptor atoms ( $\Delta G_{lipo}$ ); the loss of binding energy due to the freezing of internal degrees of freedom in the ligand, i.e., the freedom of rotation about each C-C bond is reduced ( $\Delta G_{rot}$ ); the 15 energy of the interaction between the protein and ligand ( $E_{vdw}$ ). Consideration of these terms gives equation 1:

$$(\Delta G_{bind}) = (\Delta G_0) + (\Delta G_{hb} \times N_{hb}) + (\Delta G_{ionic} \times N_{ionic}) + (\Delta G_{lipo} \times N_{lipo}) + (\Delta G_{rot} \times N_{rot}) + (E_{vdw}) .$$

Where  $N$  is the number of qualifying interactions for a specific term and, in one embodiment,  $\Delta G_0$ ,  $\Delta G_{hb}$ ,  $\Delta G_{ionic}$ ,  $\Delta G_{lipo}$  and  $\Delta G_{rot}$  are constants which are given the 20 values: 5.4, -4.7, -4.7, -0.17, and 1.4, respectively.

The term  $N_{hb}$  is calculated according to equation 2:

$$N_{hb} = \sum_{h-bonds} f(\Delta R, \Delta \alpha) \times f(N_{neighb}) \times f_{pc}$$

$f(\Delta R, \Delta \alpha)$  is a penalty function which accounts for large deviations of hydrogen bonds from ideality and is calculated according to equation 3:

25  $f(\Delta R, \Delta \alpha) = f1(\Delta R) \times f2(\Delta \alpha)$

Where:  $f1(\Delta R) = 1$  if  $\Delta R \leq TOL$

or  $= 1 - (\Delta R - TOL)/0.4$  if  $\Delta R \leq 0.4 + TOL$

or  $= 0$  if  $\Delta R > 0.4 + TOL$

And:  $f2(\Delta \alpha) = 1$  if  $\Delta \alpha < 30^\circ$

30 or  $= 1 - (\Delta \alpha - 30)/50$  if  $\Delta \alpha \leq 80^\circ$

or  $= 0$  if  $\Delta \alpha > 80^\circ$

TOL is the tolerated deviation in hydrogen bond length = 0.25 Å

27 / 38

$\Delta R$  is the deviation of the H-O/N hydrogen bond length from the ideal value = 1.9 Å

$\Delta\alpha$  is the deviation of the hydrogen bond angle  $\angle_{\text{N}=\text{O}-\text{H}-\text{O}/\text{N}}$  from its idealized value of 180°

$f(N_{\text{neighb}})$  distinguishes between concave and convex parts of a protein surface and

5 therefore assigns greater weight to polar interactions found in pockets rather than those found at the protein surface. This function is calculated according to equation 4 below:

$$f(N_{\text{neighb}}) = (N_{\text{neighb}}/N_{\text{neighb},0})^\alpha \quad \text{where } \alpha = 0.5$$

$N_{\text{neighb}}$  is the number of non-hydrogen protein atoms that are closer than 5 Å to any given protein atom.

10  $N_{\text{neighb},0}$  is a constant = 25

$f_{\text{pCS}}$  is a function which allows for the polar contact surface area per hydrogen bond and therefore distinguishes between strong and weak hydrogen bonds and its value is determined according to the following criteria:

$$f_{\text{pCS}} = \beta \text{ when } A_{\text{polar}}/N_{\text{HB}} < 10 \text{ Å}^2$$

15 or  $f_{\text{pCS}} = 1 \text{ when } A_{\text{polar}}/N_{\text{HB}} > 10 \text{ Å}^2$

$A_{\text{polar}}$  is the size of the polar protein-ligand contact surface

$N_{\text{HB}}$  is the number of hydrogen bonds

$\beta$  is a constant whose value = 1.2

For the implementation of the modified Böhm scoring function, the contributions from 20 ionic interactions,  $\Delta G_{\text{ionic}}$ , are computed in a similar fashion to those from hydrogen bonds described above since the same geometry dependency is assumed.

The term  $N_{\text{lip}}$  is calculated according to equation 5 below:

$$N_{\text{lip}} = \sum_{\text{LL}} f(r_{\text{LL}})$$

$f(r_{\text{LL}})$  is calculated for all lipophilic ligand atoms, L, and all lipophilic protein atoms, L,

25 according to the following criteria:

$$f(r_{\text{LL}}) = 1 \text{ when } r_{\text{LL}} \leq R_1 \quad f(r_{\text{LL}}) = (r_{\text{LL}} - R_1) / (R_2 - R_1) \text{ when } R_2 < r_{\text{LL}} > R_1$$

$$f(r_{\text{LL}}) = 0 \text{ when } r_{\text{LL}} \geq R_2$$

$$\text{Where: } R_1 = r_1^{\text{vdw}} + r_L^{\text{vdw}} + 0.5$$

30 and  $R_2 = R_1 + 3.0$

and  $r_i^{\text{vdw}}$  is the Van der Waal's radius of atom I

and  $r_L^{\text{vdw}}$  is the Van der Waal's radius of atom L

The term  $N_{rot}$  is the number of rotatable bonds of the amino acid side chain and is taken to be the number of acyclic  $sp^3 - sp^3$  and  $sp^3 - sp^2$  bonds. Rotations of terminal  $-CH_3$  or  $-NH_3$  are not taken into account.

The final term,  $E_{vdw}$ , is calculated according to equation 6 below:

5  $E_{vdw} = \epsilon_1 \epsilon_2 ((r_1^{vdw} + r_2^{vdw})^{12}/r^{12} - (r_1^{vdw} + r_2^{vdw})^6/r^6)$ , where:

$\epsilon_1$  and  $\epsilon_2$  are constants dependant upon atom identity

$r_1^{vdw} + r_2^{vdw}$  are the Van der Waal's atomic radii

$r$  is the distance between a pair of atoms.

With regard to Equation 6, in one embodiment, the constants  $\epsilon_1$  and  $\epsilon_2$  are given the atom

10 values: C: 0.245, N: 0.283, O: 0.316, S: 0.316, respectively (i.e. for atoms of Carbon, Nitrogen, Oxygen and Sulphur, respectively). With regards to equations 5 and 6, the Van der Waal's radii are given the atom values C: 1.85, N: 1.75, O: 1.60, S: 2.00Å.

It should be understood that all predetermined values and constants given in the equations above are determined within the constraints of current understandings of protein ligand

15 interactions with particular regard to the type of computation being undertaken herein.

Therefore, it is possible that, as this scoring function is refined further, these values and constants may change hence any suitable numerical value which gives the desired results in terms of estimating the binding energy of a protein to a ligand may be used and hence fall within the scope of the present invention.

20 As described above, the scoring function is applied to data extracted from the database of side-chain conformations, atom identities, and interatomic distances. For the purposes of the present description, the number of MHC Class II molecules included in this database is 42 models plus four solved structures. It should be apparent from the above

descriptions that the modular nature of the construction of the computational method of

25 the present invention means that new models can simply be added and scanned with the peptide backbone library and side-chain conformational search function to create additional data sets which can be processed by the peptide scoring function as described

above. This allows for the repertoire of scanned MHC Class II molecules to easily be

increased, or structures and associated data to be replaced if data are available to create

30 more accurate models of the existing alleles.

The present prediction method can be calibrated against a data set comprising a large number of peptides whose affinity for various MHC Class II molecules has previously been experimentally determined. By comparison of calculated versus experimental data,

a cut off value can be determined above which it is known that all experimentally determined T-cell epitopes are correctly predicted.

It should be understood that, although the above scoring function is relatively simple compared to some sophisticated methodologies that are available, the calculations are

5 performed extremely rapidly. It should also be understood that the objective is not to calculate the true binding energy *per se* for each peptide docked in the binding groove of a selected MHC Class II protein. The underlying objective is to obtain comparative binding energy data as an aid to predicting the location of T-cell epitopes based on the primary structure (i.e. amino acid sequence) of a selected protein. A relatively high  
10 binding energy or a binding energy above a selected threshold value would suggest the presence of a T-cell epitope in the ligand. The ligand may then be subjected to at least one round of amino-acid substitution and the binding energy recalculated. Due to the rapid nature of the calculations, these manipulations of the peptide sequence can be performed interactively within the program's user interface on cost-effectively available  
15 computer hardware. Major investment in computer hardware is thus not required.

It would be apparent to one skilled in the art that other available software could be used for the same purposes. In particular, more sophisticated software which is capable of docking ligands into protein binding-sites may be used in conjunction with energy minimization. Examples of docking software are: DOCK (Kuntz *et al.*, *J. Mol. Biol.*,

20 161:269-288 (1982)), LUDI (Böhm, H.J., *J. Comput Aided Mol. Des.*, 8:623-632 (1994)) and FLEXX (Rarey M., *et al.*, *ISMB*, 3:300-308 (1995)). Examples of molecular modeling and manipulation software include: AMBER (Tripos) and CHARMM (Molecular Simulations Inc.). The use of these computational methods would severely limit the throughput of the method of this invention due to the lengths of processing time  
25 required to make the necessary calculations. However, it is feasible that such methods could be used as a 'secondary screen' to obtain more accurate calculations of binding energy for peptides which are found to be 'positive binders' via the method of the present invention.

The limitation of processing time for sophisticated molecular mechanic or molecular  
30 dynamic calculations is one which is defined both by the design of the software which makes these calculations and the current technology limitations of computer hardware. It may be anticipated that, in the future, with the writing of more efficient code and the

continuing increases in speed of computer processors, it may become feasible to make such calculations within a more manageable time-frame.

Further information on energy functions applied to macromolecules and consideration of the various interactions that take place within a folded protein structure can be found in:

- 5 Brooks, B.R., *et al.*, *J. Comput. Chem.*, 4:187-217 (1983) and further information concerning general protein-ligand interactions can be found in: Dauber-Osguthorpe *et al.*, *Proteins* 4(1):31-47(1988), which are incorporated herein by reference in their entirety. Useful background information can also be found, for example, in Fasman, G.D., ed., *Prediction of Protein Structure and the Principles of Protein Conformation*, Plenum
- 10 Press, New York, ISBN: 0-306 4313-9.

## EXAMPLE 2

The interaction between MHC, peptide and T-cell receptor (TCR) provides the structural basis for the antigen specificity of T-cell recognition. T-cell proliferation assays test the binding of peptides to MHC and the recognition of MHC/peptide complexes by the TCR. *In vitro* T-cell proliferation assays of the present example, involve the stimulation of peripheral blood mononuclear cells (PBMCs), containing antigen presenting cells (APCs) and T-cells. Stimulation is conducted *in vitro* using synthetic peptide antigens, and in some experiments whole protein antigen. Stimulated T-cell proliferation is measured using  $^3\text{H}$ -thymidine ( $^3\text{H}$ -Thy) and the presence of incorporated  $^3\text{H}$ -Thy assessed using scintillation counting of washed fixed cells.

Buffy coats from human blood stored for less than 12 hours were obtained from the National Blood Service (Addenbrooks Hospital, Cambridge, UK). Ficoll-paque was obtained from Amersham Pharmacia Biotech (Amersham, UK). Serum free AIM V media for the culture of primary human lymphocytes and containing L-glutamine, 50 $\mu\text{g}/\text{ml}$  streptomycin, 10 $\mu\text{g}/\text{ml}$  gentomycin and 0.1% human serum albumin was from Gibco-BRL (Paisley, UK). Synthetic peptides were obtained from Eurosequence (Groningen, The Netherlands) and Babraham Technix (Cambridge, UK).

30

Erythrocytes and leukocytes were separated from plasma and platelets by gentle centrifugation of buffy coats. The top phase (containing plasma and platelets) was

removed and discarded. Erythrocytes and leukocytes were diluted 1:1 in phosphate buffered saline (PBS) before layering onto 15ml ficoll-paque (Amersham Pharmacia, Amersham UK). Centrifugation was done according to the manufacturers recommended conditions and PBMCs were harvested from the serum+PBS/ficoll paque interface.

5 PBMCs were mixed with PBS (1:1) and collected by centrifugation. The supernatant was removed and discarded and the PBMC pellet resuspended in 50ml PBS. Cells were again pelleted by centrifugation and the PBS supernatant discarded. Cells were resuspended using 50ml AIM V media and at this point counted and viability assessed using trypan blue dye exclusion. Cells were again collected by centrifugation and the supernatant 10 discarded. Cells were resuspended for cryogenic storage at a density of  $3 \times 10^7$  per ml. The storage medium was 90%(v/v) heat inactivated AB human serum (Sigma, Poole, UK) and 10%(v/v) DMSO (Sigma, Poole, UK). Cells were transferred to a regulated freezing container (Sigma) and placed at  $-70^{\circ}\text{C}$  overnight. When required for use, cells were thawed rapidly in a water bath at  $37^{\circ}\text{C}$  before transferring to 10ml pre-warmed AIM V 15 medium.

PBMC were stimulated with protein and peptide antigens in a 96 well flat bottom plate at a density of  $2 \times 10^5$  PBMC per well. PBMC were incubated for 7 days at  $37^{\circ}\text{C}$  before pulsing with  $^3\text{H}$ -Thy (Amersham-Pharmacia, Amersham, UK). For the present study, 20 synthetic peptides (15mers) that overlapped by 12 amino acids were generated that spanned the entire sequence of bryodin 1. Peptide identification numbers (ID#) and sequences are given in FIGURE 2. Each peptide was screened individually against PBMC's isolated from 21 naïve donors. Two control peptides that have previously been shown to be immunogenic and a potent non-recall antigen KLH were used in each donor 25 assay.

The control antigens used in this study were as below:

Peptide	Sequence
C-32	Biotin-PKYVKQNTLKLAT Flu haemagglutinin 307-319
C-49	KVVDQIKKISKPVQH Chlamydia HSP 60 peptide
KLH	Whole protein from Keyhole

52 / 38

  | Limpet Hemocyanin.

Peptides were dissolved in DMSO to a final concentration of 10mM, these stock solutions were then diluted 1/500 in AIM V media (final concentration 20 $\mu$ M). Peptides were added to a flat bottom 96 well plate to give a final concentration of 2 and 20 $\mu$ M in a 5 100 $\mu$ l. The viability of thawed PBMC's was assessed by trypan blue dye exclusion, cells were then resuspended at a density of  $2 \times 10^6$  cells/ml, and 100 $\mu$ l ( $2 \times 10^5$  PBMC/well) was transferred to each well containing peptides. Triplicate well cultures were assayed at each peptide concentration. Plates were incubated for 7 days in a humidified atmosphere of 10 5% CO<sub>2</sub> at 37°C. Cells were pulsed for 18-21 hours with 1 $\mu$ Ci <sup>3</sup>H-Thy/well before harvesting onto filter mats. CPM values were determined using a Wallac microplate beta top plate counter (Perkin Elmer). Results were expressed as stimulation indices, determined using the following formula:

Proliferation to test peptide CPM

Proliferation in untreated wells CPM

15 Mapping T cell epitopes in the bryodin 1 sequence using the T cell proliferation assay resulted in the identification of five major immunogenic regions encompassed by peptide ID#16-18, 30, 38-41, 46-50 and 60-64. For each of these peptides, responsive donors showed a stimulation index >2.0.

20

Patent Claims

1. A modified molecule having the biological activity of bryodin 1 and being substantially non-immunogenic or less immunogenic than any non-modified molecule having the same biological activity when used *in vivo*.
2. A molecule of claim 1, wherein said loss of immunogenicity is achieved by removing one or more T-cell epitopes derived from the originally non-modified molecule.
3. A molecule of claim 2, wherein said loss of immunogenicity is achieved by reduction in numbers of MHC allotypes able to bind peptides derived from said molecule.
4. A molecule of claim 2 or 3, wherein one T-cell epitope is removed; an accordingly specified molecule, wherein said originally present T-cell epitopes are MHC class II ligands or peptide sequences which show the ability to stimulate or bind T-cells via presentation on class II.
5. A molecule of any of the claims 1 – 4, wherein said peptide sequences are selected from the group as depicted in FIGURE 1.
6. A molecule according to any of the claims 1 – 5, wherein 1 – 9 amino acid residues, preferably one amino acid residue in any of the originally present T-cell epitopes are altered; an accordingly specified molecule, wherein the alteration of the amino acid residues is substitution, addition or deletion of originally present amino acid(s) residue(s) by other amino acid residue(s) at specific position(s).
7. A molecule of claim 6, wherein, if necessary, additionally further alteration usually by substitution, addition or deletion of specific amino acid(s) is conducted to restore biological activity of said molecule.

34/38

8. A peptide molecule of any of the above-cited claims sharing greater than 90% amino acid identity with any of the peptide sequences of FIGURE 1.
9. A peptide molecule of claim 8 sharing greater than 80% amino acid identity with any of the peptide sequences of FIGURE 1.

5

10. A peptide sequence according to any of the claims 1 – 9, that are able to bind MHC class II.

11. A bryodin 1 molecule according to any of the claims 1 – 10, wherein one or more of the amino acid substitutions is conducted at a position corresponding to any of the amino acids specified within FIGURE 1.

12. A molecule of claim 11, wherein alteration is conducted at one or more residues from any or all of the string of contiguous residues of sequences:

15 (a) ITTLYYYTASSAASALLVLIQSTAESA,  
(b) = ATEAAKFVFKDAKKK,  
(c) = ERLQTAAGKIRENIPLGLPALDSA,  
(d) = ITTLYYYTASSAASALLVLIQSTAESA,  
(e) = TFLPSLATISLENNWSALSKQIQIAST,

20 wherein said sequences are derived from the bryodin 1 wild-type sequence.

13. A peptide molecule of claim 12, comprising 13–15 consecutive residues from any of sequences (a), (b), (c), (d) or (e).

25 14. A peptide molecule of claim 12, comprising at least 9 consecutive residues from any of the sequences (a), (b), (c) (d) or (e).

15. A peptide molecule according to claims 12 – 14, sharing greater than 90% amino acid identity with any of the peptide sequences derived from (a), (b), (d) or (e)  
30 above;

16. A peptide molecule of claims 12 – 14, sharing greater than 80% amino acid identity with any of the peptide sequences derived from (a), (b), (c) (d) or (e).

17. A peptide sequences of any of the claims 12 – 16, that are able to bind MHC class II;
18. A bryodin 1 molecule, wherein one or more of the amino acid substitutions is conducted at a position corresponding to any of the amino acids specified within any of sequences (a), (b), (c), (d) or (e) of claim 12.
19. A bryodin 1 molecule of claim 18, wherein one or more of the amino acid substitutions is conducted at a position corresponding to any of the amino acids specified within sequence (b) above.
20. A peptide sequence consisting of at least 9 consecutive amino acid residues of any of the sequences (a), (b), (c), (d) or (e) of claim 12 and its use for the manufacture of bryodin 1,  $\alpha$ -trichosanthin,  $\alpha$ -momorcharin or  $\beta$ -momorcharin having substantially no or less immunogenicity than any non-modified molecule and having the biological activity of a type 1 RIP when used *in vivo*.
21. A pharmaceutical composition comprising any of the peptides or modified peptides of any of the claims 1 - 20 having the activity of binding to MHC class II.
22. A DNA sequence or molecule which codes for any of said specified modified molecules as defined above and below.
23. A pharmaceutical composition comprising a modified molecule according to any of the claims 1 – 20 having the biological activity of bryodin 1.
24. A pharmaceutical composition of claim 23, optionally together with a pharmaceutically acceptable carrier, diluent or excipient.
25. A method for manufacturing a modified molecule having the biological activity of bryodin 1 as defined in any of the claims of the above-cited claims comprising the following steps: (i) determining the amino acid sequence of the polypeptide or part thereof; (ii) identifying one or more potential T-cell epitopes within the amino

acid sequence of the protein by any method including determination of the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays; (iii) designing new sequence variants with one or more amino acids within the identified potential T-cell epitopes modified in such a way to substantially reduce or eliminate the activity of the T-cell epitope as determined by the binding of the peptides to MHC molecules using *in vitro* or *in silico* techniques or biological assays; (iv) constructing such sequence variants by recombinant DNA techniques and testing said variants in order to identify one or more variants with desirable properties; and (v) optionally repeating steps (ii) – (iv).

26. A method of claim 25, wherein step (iii) is carried out by substitution, addition or deletion of 1 – 9 amino acid residues in any of the originally present T-cell epitopes.

27. A method of claim 25 or 26, wherein the alteration is made with reference to an homologous protein sequence and / or *in silico* modeling techniques.

28. A method of any of the claims 25 – 27, wherein step (ii) of above is carried out by the following steps: (a) selecting a region of the peptide having a known amino acid residue sequence; (b) sequentially sampling overlapping amino acid residue segments of predetermined uniform size and constituted by at least three amino acid residues from the selected region; (c) calculating MHC Class II molecule binding score for each said sampled segment by summing assigned values for each hydrophobic amino acid residue side chain present in said sampled amino acid residue segment; and (d) identifying at least one of said segments suitable for modification, based on the calculated MHC Class II molecule binding score for that segment, to change overall MHC Class II binding score for the peptide without substantially reducing therapeutic utility of the peptide; step (c) is preferably carried out by using a Böhm scoring function modified to include 12-6 van der Waal's ligand-protein energy repulsive term and ligand conformational energy term by (1) providing a first data base of MHC Class II molecule models; (2) providing a second data base of allowed peptide backbones for said MHC

Class II molecule models; (3) selecting a model from said first data base; (4) selecting an allowed peptide backbone from said second data base; (5) identifying amino acid residue side chains present in each sampled segment; (6) determining the binding affinity value for all side chains present in each sampled segment; and repeating steps (1) through (5) for each said model and each said backbone.

5 29. A 13mer T-cell epitope peptide having a potential MHC class II binding activity and created from non-modified bryodin 1, selected from the group as depicted in FIGURE 1 and its use for the manufacture of bryodin 1 having substantially no or less immunogenicity than any non-modified molecule with the same biological activity when used *in vivo*.

10

30. A peptide sequence consisting of at least 9 consecutive amino acid residues of a 13mer T-cell epitope peptide as specified above and its use for the manufacture of bryodin having substantially no or less immunogenicity than any non-modified molecule and having the biological activity of bryodin 1 when used *in vivo*.

15

31. A 13mer T-cell epitope peptide having a potential MHC class II binding activity and created from non-modified bryodin 1, selected from any of the group of sequences (FIGURE 1) and its use for the manufacture of bryodin 1 having substantially no or less immunogenicity than any non-modified molecule and having the biological activity of a bryodin 1 molecule when used *in vivo*.

20

32. A peptide sequence consisting of at least 9 consecutive amino acid residues of a 13mer T-cell epitope peptide as derived from any of the sequences in FIGURE 1 and its use for the manufacture of bryodin 1 having substantially no or less immunogenicity than any non-modified molecule and having the biological activity of a bryodin molecule when used *in vivo*.

25

30

**Abstract**

The present invention relates to polypeptides to be administered especially to humans and  
5 in particular for therapeutic use. The polypeptides are modified polypeptides whereby the  
modification results in a reduced propensity for the polypeptide to elicit an immune  
response upon administration to the human subject. The invention in particular relates to  
the modification of bryodin 1 to result in bryodin 1 proteins that are substantially non-  
immunogenic or less immunogenic than any non-modified counterpart when used *in vivo*.  
10 The invention relates furthermore to T-cell epitope peptides derived from said non-  
modified protein by means of which it is possible to create modified bryodin 1 variants  
with reduced immunogenicity.

1/3

## FIGURE 1

VSFRILSGATTSY,	FRLSGATTSYGV,	TSYGVFIKNLREA,
YGVFIKNLREALP,	GVFIKNLREALPY,	VFIKNLREALPYE,
KNLREALPYERKV,	EALPYERKVYNIP,	LPYERKVYNIPPL,
RKVYNIPLLRSSI,	KVYNIPLLRSSIS,	YNIPLLRSSISGGS,
IPLLRSISGSGR,	PLLRSISGSGRY,	SSISGSGRYTLLH,
GRYTLLHLTNYAD,	YTLHLTNYADET,	TLLHLTNYADETI,
LHLTNYADETISV,	TNYADETISVAVD,	ETISVAVDVTNVY,
ISVAVDVTNVYIM,	VAVDVTNVYIMGY,	VDVTNVYIMGYLA,
TNVYIMGYLAGDV,	NVYIMGYLAGDVS,	VYIMGYLAGDVSY,
YIMGYLAGDVSYF,	MGYLAGDVSYFFN,	GYLAGDVSYFFNE,
GDVSYFFNEASAT,	VSYFFNEASATEA,	SYFFNEASATEAA,
YFFNEASATEAAK,	AKFVFKDAKKVTL,	KFVFKDAKKVTL,
FVFKDAKKVTLIP,	KKVTLPSGNYER,	VTLPSGNYERLQ,
LPYSGNYERLQTA,	GNYERLQTAAGKI,	ERLQTAAGKIREN,
GKIRENIPLGLPA,	ENIPLGLPALDSA,	IPLGLPALDSAIT,
LGLPALDSAITT,	PALDSAITTLYYY,	SAITTLYYYTASS,
TTLYYYTASSAAS,	TLYYYTASSAASA,	LYYYTASSAASAL,
YYYTASSAASALL,	SALLVLIQSTAES,	ALLVLIQSTAESA,
LLVLIQSTAESAR,	LVLQSTAESARY,	VLIQSTAESARYK,
ARYKFIEQQIGKR,	YKFIEQQIGKRVD,	KFIEQQIGKRVDK,
QQIGKRVDKTFLP,	KRVDKTFPLPSLAT,	KTFPLPSLATISLE,
TFLPSLATISLEN,	PSLATISLENNWS,	ATISLENNWSALS,
ISLENNWSALSKQ,	NNWSALSKQIQIA,	SALSKQIQIASTN,
KQIQIASTNNQF,	IQIASTNNQFES,	GQFESPVVLIDGN,
SPVVLIDGNNQRV,	PVVLIDGNNQRVS,	VVLIDGNNQRVSI,
VLIDGNNQRVSIT,	QRVSITNASARVV,	VSITNASARVVT,
ARVVTSNIAILLN,	RVVTSNIAILLNR,	SNIAILLNRNNIA,
IALLLNRRNIAAI,	ALLLNRRNIAAIG,	LLLNRRNIAAIGE,
NNIAAIGEDISMT,	AAIGEDISMTLIG,	EDISMTLIGFEHG,
ISMTLIGFEHGLY,	MTLIGFEHGLYGI,	

2/3

## FIGURE 2

Peptide ID #	Bryodin1; 15mer peptide sequence	Residue #
1	DVSFRLSGATTTSYCG	1
2	FRLSGATTTSYGVFI	4
3	SGATTSYGVFIKNL	7
4	TTTSYGVFIKNLREA	10
5	SYGVFIKNLREALPY	13
6	VFIKNLREALPYERK	16
7	KNLREALPYERKVYN	19
8	REALPYERKVYNIPPL	22
9	LPYERKVYNIPPLRS	25
10	ERKVYNIPPLRSSIS	28
11	VYNIPPLRSSISGSG	31
12	IPPLRSSISGSGRYT	34
13	LRSSISGSGRYTLLH	37
14	SISGSGRYTLLHLTN	40
15	GSGRYTLLHLTNYAD	43
16	RYTLLHLTNYADETI	46
17	LLHLTNYADETISVA	49
18	LTNYADETISVAVDV	52
19	YADETISVAVDVTVNV	55
20	ETISVAVDVTVNVYIM	58
21	SVAVDVTVNVYIMGYL	61
22	VDVTNVYIMGYLAGD	64
23	TNVYIMGYLAGDVEY	67
24	YIMGYLAGDVSYIFFN	70
25	GYLAGDVSYIFFNEAS	73
26	ACDVSYIFFNEASATE	76
27	VSYEFFNEASATEAAK	79
28	FFNEASATEAAKVF	82
29	ERASATEAAKVFVERDA	85
30	ATEAAKVFVDAKKRK	88
31	AAKVFVDAKKRKVTI	91
32	EVFKDAKKRKVTLPYS	94
33	EDAKRKVTLPYSGNY	97
34	ERKVTLPYSGNYERL	100
35	VTLPPYSGNYERLQTA	103
36	PYSGNYERLQTAAGK	106
37	GNYERLQTAAGKIRE	109
38	ERLQTAAGKIRENIP	112
39	QTAAGKIRENIPLGL	115
40	AGKIRENIPLGLPAL	118
41	IRENIPLGLPALDSA	121
42	NIPLGLPALDSAITT	124
43	LGLPALDSAITTLY	127

Peptide ID #	Bryodin1; 15mer peptide sequence	Residue #
44	FALDSAITTLYYYTA	130
45	DSAITTLYYYTASSA	133
46	ITTLYYYYTASSAASA	136
47	LYYYTASSAASAALLV	139
48	YASSAASAALLVLIQ	142
49	SSAASALLVLIQSTA	145
50	ASALLVLIQSTAESA	148
51	LLVLIQSTAESAERYK	151
52	LQSTAESAERYKFIIE	154
53	STAESAERYKFIIEQQI	157
54	ESAKYKFIIEQQIGKR	160
55	RYKFIIEQQIGKRVDK	163
56	FIEQQIGKRVDKTFL	166
57	QQICKRVDKTFPLSL	169
58	GRKVDTKTFPLSLATI	172
59	VDKTFPLSLATISLE	175
60	TFPLSLATISLENNW	178
61	PSLATISLENNWSAL	181
62	ATISLENNWSALSKQ	184
63	SLENNWSALSKQIQC	187
64	NNWSALSKQIQCIAST	190
65	SALSKQIQCIASTNNG	193
66	SKQIQCIASTNNNGQFE	196
67	IQCIASTNNNGQFESPV	199
68	ASTNNNGQFESPVVLI	202
69	NNNGQFESPVVLIQDN	205
70	QFESPVVLIQDNQNR	208
71	SPVVLIDCQNNQRVSI	211
72	VLIQDNQQRVSIQVTA	214
73	DQNNQRVSIQVTA	217
74	NQRVSIQVTA	220
75	VSIQVTA	223
76	TNAQVTVTSNIALL	226
77	SARVTVTSNIALLNR	229
78	VVTTSNIALLNRNNI	232
79	SNIALLNRNNIAAI	235
80	ALLNRNNIAAIQED	238
81	LNRNNIAAIQEDISM	241
82	NNIAAIQEDISMIL	244
83	AIQEDISMILIGFE	247
84	QEDISMILIGFEHGL	250
85	ISMTLIGFEHGLYGI	253

3/3

**FIGURE 3****Epitope R1 (residues 46-66)**

1BRY	RYTLLHLTNYADETISVAVDV
1TCS	::A:I:::::::::::I::
1CF5	:F:I::::S::Y::::::::::

**Epitope R2 (residues 88-102)**

1BRY	ATEAAKFVFKA
1TCS	::::::Y:::::MR:

**Epitope R3 (residues 112-135)**

1BRY	ERLQTAAGKIRENIPILGLPALDSA
1TCS	:::::::::::::::::::
1CF5	:N::::H::::::::::S::
1MOM	::::I::::P::K::I::::::

**Epitope R4 (residues 136-162)**

1BRY	ITTLYYYTASSAASALLVLIQSTAESA
1TCS	:::::F:::N:N:::::M:::::S:A:
1CF5	:::::F:::N:Q::P:::::T:::A:
1MOM	::S::LH:DSTA::G:::::T:::A:

**Epitope R5 (residues 178-204)**

1BRY	TFLPSLATISLENNWSALSKQIQIAST
1TCS	::::::I::::S:::::::::::
1CF5	N:K::::I::::Q::::::::::FL:QN
1MOM	DEV::::::::::S:::G:::::L:QG